Ainos, Inc. (AIMD)
NASDAQ: AIMD · IEX Real-Time Price · USD
0.750
+0.019 (2.59%)
At close: Jul 19, 2024, 4:00 PM
0.730
-0.020 (-2.67%)
Pre-market: Jul 22, 2024, 7:21 AM EDT
Ainos Revenue
Ainos had revenue of $-28.44K in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $20.73K.
Revenue (ttm)
$-28.44K
Revenue Growth
-25.24%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
46
Market Cap
5.75M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 594.56K | 578.00K | 3,489.71% |
| Dec 31, 2020 | 16.56K | 4.83K | 41.19% |
| Dec 31, 2019 | 11.73K | -65.99K | -84.91% |
| Dec 31, 2018 | 77.72K | -173.20K | -69.03% |
| Dec 31, 2017 | 250.93K | - | - |
| Dec 31, 2016 | 0 | - | - |
| Dec 31, 2015 | 0 | - | - |
| Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sonoma Pharmaceuticals | 12.74M |
| Biomerica | 5.41M |
| TFF Pharmaceuticals | 885.72K |
| Titan Pharmaceuticals | 87.00K |
| Oragenics | 20.63K |
AIMD News
- 5 weeks ago - Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA - Accesswire
- 2 months ago - Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market - Accesswire
- 2 months ago - Ainos Reports First Quarter 2024 Financial Results - Accesswire
- 2 months ago - Ainos Raises $9 Million in Growth Capital with Existing Shareholder - Accesswire
- 4 months ago - Ainos Reports Full Year 2023 Financial Results - Accesswire
- 5 months ago - Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms - Accesswire
- 6 months ago - Ainos Announces $1.75 Million Follow-On Funding - Accesswire
- 7 months ago - Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement - Accesswire